Instruction for use: Axamon

Active substance: Ipidacrine

ATX Code

N07AA Anticholinesterase drugs

Pharmacological group

Cholinesterase inhibitor [m-, n-cholinomimetics, incl. Anticholinesterase drugs]

The nosological classification (ICD-10)

F03 Dementia, unspecified

Degenerative dementia, Dementia, Dementia presenilnaya,Dementia senile,Primary degenerative dementia, Senile dementia, Senile dementia of the Alzheimer's type, Syndromes of dementia, Dementia, Mixed Dementia, Mixed forms of dementia, Senile Dementia

G12.2 Disease of the motor neuron

Tropical spastic paraparesis, Amyotrophic lateral sclerosis, Bulbar Pallas, Bulbar palsy, Amyotrophic lateral sclerosis, Diseases of motor neurons, Amyotrophic lateral sclerosis, Low-Gehrig's disease, Charcot's disease, Amyotrophic amyotrophic sclerosis, Sclerosis lateral primary, Progressive pseudobulbar palsy, Progressive bulbar palsy, Primary lateral sclerosis

G30 Alzheimer's disease

Alzheimer's Disease

G37 Other demyelinating diseases of the central nervous system

G62 Other polyneuropathies

Polyneuritis, Polineuropathy, Inflammation of peripheral nerves

G63.6 Polyneuropathy with other musculoskeletal lesions (M00-M25 +, M40-M96 +)

Polyradiculoneuropathy

G70 Myasthenia gravis and other disorders of the neuromuscular synapse

Myasthenic syndrome, Myasthenic syndromes, Myasthenia gravis, Myasthenic syndrome, Severe myasthenia gravis (Myasthenia gravis)

G83.9 Paralytic syndrome, unspecified

bulbar paresis, bulbar palsy

G92 Toxic encephalopathy

Alcohol encephalopathy, Toxic brain damage, Toxic damage to the central nervous system, Encephalopathy in chronic alcoholism, Brain Injury Toxic, Encephalopathy against alcoholism, Acute lead encephalopathy

G93.4 Unspecified encephalopathy

Bilirubin encephalopathy, Lacunar status, Tremor in portal-systemic encephalopathy, Latent hepatic encephalopathy, Atherosclerotic encephalopathy, Hypertonic encephalopathy, Hypoxic encephalopathy, Dysmetabolic encephalopathy, Encephalopathy,Defeat of the brain, Porto-caval encephalopathy, Vascular encephalopathy, Traumatic encephalopathy, Encephalopathy, Encephalopathy of secondary origin, Encephalopathy dyscirculatory, Encephalopathy portocaval, Epileptic encephalopathy, Syndrome of hemorrhagic shock and encephalopathy, Subacute spongiform encephalopathy

G96.9 Disorder of central nervous system, unspecified

Toxic damage to the central nervous system, CNS depression, Violation of the functions of the central nervous system, Functional deficiency of the nervous system, Traumatic injury of the central nervous system, Hereditary disease of the central nervous system, Hereditary diseases of the nervous system

I67.4 Hypertensive encephalopathy

Encephalopathy is hypertensive

M79.2 Neurology and neuritis, unspecified

Pain syndrome with neuralgia, Brachialgia, Occipital and intercostal neuralgia, Neuralgia, Neuralgic pain, Neuralgia, Neuralgia of intercostal nerves,Neuralgia of the posterior tibial nerve, Neuritis, Neuritis traumatic, Neuritis, Neurological Pain Syndromes, Neurological contractures with spasms, Acute neuritis, Peripheral neuritis,Post-traumatic neuralgia,Severe pain of a neurogenic nature, Chronic neuritis, Essential neuralgia

Composition

Tablets 1 table.

active substance:

Ipidacrine hydrochloride monohydrate (Aksamon®) 20 mg

(In terms of ipidacrine hydrochloride)

Auxiliary substances: ludipress (lactose monohydrate - 93%, povidone - 3.5%, crospovidone - 3.5%) - 65 mg; Sodium carboxymethyl starch - 14 mg; Calcium stearate - 1 mg

pharmachologic effect

Pharmacological action - anticholinesterase, stimulating neuromuscular transmission.

Dosing and Administration

Inside. Doses and duration of treatment are determined individually, depending on the severity of the disease.

Diseases of the peripheral nervous system, myasthenia gravis, myasthenic syndrome: 10-20 mg 1-3 times a day. The course of treatment - from 1 to 2 months. If necessary, the course of treatment can be repeated several times with a break between courses in 1-2 months.

Alzheimer's disease, encephalopathy, the recovery period of organic CNS diseases accompanied by motor disorders, incl. Bulbar paralysis and paresis: a daily dose is selected individually, usually 10-20 mg 2-3 times a day.

With demyelinating lesions of the nervous system, the dose can be increased to 20-40 mg 5-6 times a day. The maximum daily dose is 200 mg.

If one of the techniques was missed, the next dose is taken as a usual dose of the drug.

Relies Form

Tablets, 20 mg. For 10 tab. In a planar cell package. 5 contour mesh packages are placed in a pack of cardboard.

Terms of leave from pharmacies

On prescription.

Storage conditions

In dry, the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life

3 years.

Do not use after the expiry date printed on the package.